Mark Foletta Sells 4,000 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 4,000 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Performance

NASDAQ DXCM opened at $72.47 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The firm has a market capitalization of $27.96 billion, a price-to-earnings ratio of 30.97, a P/E/G ratio of 1.11 and a beta of 1.45. The company’s fifty day moving average is $66.93 and its two-hundred day moving average is $67.88. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter in the prior year, the business earned $0.32 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post 2.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on DXCM. Canaccord Genuity Group set a $82.00 price target on DexCom and gave the company a “buy” rating in a report on Monday, May 18th. Citigroup reissued a “buy” rating and set a $84.00 price objective (up from $79.00) on shares of DexCom in a report on Thursday, May 28th. Bank of America lowered their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. TD Cowen restated a “buy” rating and issued a $95.00 target price (up from $75.00) on shares of DexCom in a research note on Wednesday, June 10th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $85.00 target price on shares of DexCom in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $84.83.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gradient Investments LLC raised its stake in shares of DexCom by 13.8% in the fourth quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after acquiring an additional 40,343 shares during the last quarter. Nordea Investment Management AB increased its holdings in DexCom by 118.6% during the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock valued at $16,988,000 after purchasing an additional 137,986 shares in the last quarter. NEOS Investment Management LLC increased its holdings in DexCom by 58.7% during the 3rd quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after purchasing an additional 65,066 shares in the last quarter. Banco Santander S.A. raised its position in DexCom by 28.9% in the 3rd quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock valued at $16,843,000 after purchasing an additional 56,062 shares during the last quarter. Finally, Banque Pictet & Cie SA raised its position in DexCom by 58.2% in the 4th quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock valued at $7,289,000 after purchasing an additional 40,411 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.